Literature DB >> 15862430

Multicenter intravascular ultrasound validation study among heart transplant recipients: outcomes after five years.

Jon A Kobashigawa1, Jonathan M Tobis, Randall C Starling, E Murat Tuzcu, Andrew L Smith, Hannah A Valantine, Alan C Yeung, Mandeep R Mehra, Hitoshi Anzai, Brandy T Oeser, Kamal H Abeywickrama, Jane Murphy, Nathalie Cretin.   

Abstract

OBJECTIVES: We sought to assess the validity of first-year intravascular ultrasound (IVUS) data as a surrogate marker for long-term outcome after heart transplantation.
BACKGROUND: Cardiac allograft vasculopathy (CAV) is a major impediment to long-term graft survival. Intravascular ultrasound is more sensitive than coronary angiography and detects intimal thickening (early CAV) in the coronary arteries of the donor heart. Single-center studies have suggested first-year IVUS results might be a surrogate marker for long-term outcome.
METHODS: First-year IVUS results and subsequent five-year clinical follow-up data were reviewed in 125 heart transplant recipients from five institutions. The IVUS tapes (at baseline and one year) were re-analyzed at a core IVUS laboratory. The change in maximal intimal thickness (MIT) from baseline to one year was recorded for several matched sites in the same coronary artery. Patients were classified into two groups: those with >/=0.5 mm in the MIT in any matched site (group 1) and those with MIT <0.5 mm (group 2).
RESULTS: Group 1 patients compared with group 2 patients had a higher incidence of death or graft loss (D/GL, 20.8% vs. 5.9%; p = 0.007), had more nonfatal major adverse cardiac events and/or D/GL (45.8% vs. 16.8%; p = 0.003), and had more findings of newly occurring angiographic luminal irregularities (65.2% vs. 32.6%, p = 0.004).
CONCLUSIONS: This multicenter study suggests that progression of intimal thickening >/=0.5 mm in the first year after transplantation appears to be a reliable surrogate marker for subsequent mortality, nonfatal major adverse cardiac events, and development of angiographic CAV through five years after heart transplantation.

Entities:  

Mesh:

Year:  2005        PMID: 15862430     DOI: 10.1016/j.jacc.2005.02.035

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  55 in total

Review 1.  Applications of grayscale and radiofrequency intravascular ultrasound to image atherosclerotic plaque.

Authors:  Somjot S Brar; Gary S Mintz; Akiko Maehara; Gregg W Stone
Journal:  J Nucl Cardiol       Date:  2010-10       Impact factor: 5.952

Review 2.  Transplant allograft vasculopathy: Role of multimodality imaging in surveillance and diagnosis.

Authors:  Gregory A Payne; Fadi G Hage; Deepak Acharya
Journal:  J Nucl Cardiol       Date:  2015-12-28       Impact factor: 5.952

3.  Everolimus-Eluting Bioresorbable Vascular Scaffold System in the Treatment of Cardiac Allograft Vasculopathy: the CART (Cardiac Allograft Reparative Therapy) Prospective Multicenter Pilot Study.

Authors:  Michele Pighi; Fabrizio Tomai; Alessandro Petrolini; Leonardo de Luca; Giuseppe Tarantini; Alberto Barioli; Paola Colombo; Silvio Klugmann; Marco Ferlini; Maurizio Ferrario Ormezzano; Bruno Loi; Paolo Calabrò; Renato Maria Bianchi; Giuseppe Faggian; Alberto Forni; Corrado Vassanelli; Marco Valgimigli; Flavio Ribichini
Journal:  J Cardiovasc Transl Res       Date:  2015-12-18       Impact factor: 4.132

4.  Changes in coronary anatomy and physiology after heart transplantation.

Authors:  Atsushi Hirohata; Mamoo Nakamura; Katsuhisa Waseda; Yasuhiro Honda; David P Lee; Randall H Vagelos; Sharon A Hunt; Hannah A Valantine; Paul G Yock; Peter J Fitzgerald; Alan C Yeung; William F Fearon
Journal:  Am J Cardiol       Date:  2007-04-19       Impact factor: 2.778

5.  Cardiac allograft vasculopathy: a complex multifactorial sequela of heart transplantation.

Authors:  Ana Maria Segura; L Maximilian Buja
Journal:  Tex Heart Inst J       Date:  2013

6.  Semi-quantitative myocardial perfusion MRI in heart transplant recipients at rest: repeatability in healthy controls and assessment of cardiac allograft vasculopathy.

Authors:  Travis B DeSa; Muhannad A Abbasi; Julie A Blaisdell; Kai Lin; Jeremy D Collins; James C Carr; Michael Markl
Journal:  Clin Imaging       Date:  2019-12-19       Impact factor: 1.605

Review 7.  Updates on Heart Transplantation.

Authors:  Kevin S Shah; Michelle M Kittleson; Jon A Kobashigawa
Journal:  Curr Heart Fail Rep       Date:  2019-10

Review 8.  What Is the Clinical Utility of Intravascular Ultrasound?

Authors:  Eisha Wali; Sandeep Nathan
Journal:  Curr Cardiol Rep       Date:  2018-09-28       Impact factor: 2.931

Review 9.  Immunosuppressive therapy in older cardiac transplant patients.

Authors:  Arezu Zejnab Aliabadi; Andreas Oliver Zuckermann; Michael Grimm
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

10.  In vivo prevention of transplant arteriosclerosis by ex vivo-expanded human regulatory T cells.

Authors:  Satish N Nadig; Joanna Wieckiewicz; Douglas C Wu; Gregor Warnecke; Wei Zhang; Shiqiao Luo; Alexandru Schiopu; David P Taggart; Kathryn J Wood
Journal:  Nat Med       Date:  2010-05-16       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.